Jornal de Diabetes Clínica

Abstrato

Clozapine induces metformin-resistant prediabetes/diabetes that's related to poor clinical efficaciousness in patients with early treatment-resistant schizophrenic disorder

Halin shao

Two distinct subtypes of treatment-resistant dementia praecox (TRS) are recently rumored, as well as earlytreatment resistance (E-TR) and late-treatment resistance (L-TR). This study was to assess clozapine-induced metformin-resistant prediabetes/diabetes and its correlation with clinical effectiveness in dementia praecox E-TR subtype. The incidence of clozapine-induced metformin-resistant prediabetes/diabetes was significantly high in dementia praecox early-treatment resistance (E-TR) subtype. Clozapine-induced metformin-resistantprediabetes/diabetes depicted associate degree freelance risk issue that adversely affected the clinical effectiveness of neuroleptic agent for dementia praecox E-TR subtype. Switching to neuroleptic agent strategy ought to be reconsidered within the treatment of patients with dementia praecox E-TR subtype. Given the high incidence of metformin-resistant clozapine-induced prediabetes/diabetes, the viability of manner interventions to stop clozapineinduced prediabetes/diabetes in patients with dementia praecox E-TR subtype ought to be assessed in future studies.